FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001561654> ?p ?o ?g. }

• W2001561654 endingPage "2090" @default.
• W2001561654 startingPage "2081" @default.
• W2001561654 abstract "Background— Inhibition of tyrosine kinases, including platelet-derived growth factor receptor, can reduce pulmonary arterial pressure in experimental and clinical pulmonary hypertension. We hypothesized that inhibition of the serine/threonine kinases Raf-1 (also termed c-Raf) and b-Raf in addition to inhibition of tyrosine kinases effectively controls pulmonary vascular and right heart remodeling in pulmonary hypertension. Methods and Results— We investigated the effects of the novel multikinase inhibitor sorafenib, which inhibits tyrosine kinases as well as serine/threonine kinases, in comparison to imatinib, a tyrosine kinase inhibitor, on hemodynamics, pulmonary and right ventricular (RV) remodeling, and downstream signaling in experimental pulmonary hypertension. Fourteen days after monocrotaline injection, male rats were treated orally for another 14 days with sorafenib (10 mg/kg per day), imatinib (50 mg/kg per day), or vehicle (n=12 to 16 per group). RV systolic pressure was decreased to 35.0±1.5 mm Hg by sorafenib and to 54.0±4.4 mm Hg by imatinib compared with placebo (82.9±6.0 mm Hg). In parallel, both sorafenib and imatinib reduced RV hypertrophy and pulmonary arterial muscularization. The effects of sorafenib on RV systolic pressure and RV mass were significantly greater than those of imatinib. Sorafenib prevented phosphorylation of Raf-1 and suppressed activation of the downstream ERK1/2 signaling pathway in RV myocardium and the lungs. In addition, sorafenib but not imatinib antagonized vasopressin-induced hypertrophy of the cardiomyoblast cell line H9c2. Conclusions— The multikinase inhibitor sorafenib prevents pulmonary remodeling and improves cardiac and pulmonary function in experimental pulmonary hypertension. Sorafenib exerts direct myocardial antihypertrophic effects, which appear to be mediated via inhibition of the Raf kinase pathway. The combined inhibition of tyrosine and serine/threonine kinases may provide an option to treat pulmonary arterial hypertension and associated right heart remodeling." @default.
• W2001561654 created "2016-06-24" @default.
• W2001561654 creator A5002047467 @default.
• W2001561654 creator A5006281057 @default.
• W2001561654 creator A5018770371 @default.
• W2001561654 creator A5022121355 @default.
• W2001561654 creator A5043324136 @default.
• W2001561654 creator A5043857150 @default.
• W2001561654 creator A5054116239 @default.
• W2001561654 creator A5054895539 @default.
• W2001561654 creator A5057524424 @default.
• W2001561654 creator A5061019810 @default.
• W2001561654 creator A5069563229 @default.
• W2001561654 creator A5083839456 @default.
• W2001561654 creator A5084935661 @default.
• W2001561654 creator A5089492075 @default.
• W2001561654 date "2008-11-11" @default.
• W2001561654 modified "2023-10-18" @default.
• W2001561654 title "Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling" @default.
• W2001561654 cites W1969046837 @default.
• W2001561654 cites W1980197856 @default.
• W2001561654 cites W1993536160 @default.
• W2001561654 cites W1998990808 @default.
• W2001561654 cites W2003148399 @default.
• W2001561654 cites W2011826559 @default.
• W2001561654 cites W2012317825 @default.
• W2001561654 cites W2016332264 @default.
• W2001561654 cites W2016543476 @default.
• W2001561654 cites W2018473684 @default.
• W2001561654 cites W2019813054 @default.
• W2001561654 cites W2023846004 @default.
• W2001561654 cites W2023988777 @default.
• W2001561654 cites W2025593289 @default.
• W2001561654 cites W2032937314 @default.
• W2001561654 cites W2036199559 @default.
• W2001561654 cites W2039601123 @default.
• W2001561654 cites W2045418557 @default.
• W2001561654 cites W2053383702 @default.
• W2001561654 cites W2058813449 @default.
• W2001561654 cites W2061345986 @default.
• W2001561654 cites W2063742358 @default.
• W2001561654 cites W2090134402 @default.
• W2001561654 cites W2111848059 @default.
• W2001561654 cites W2112604150 @default.
• W2001561654 cites W2114952041 @default.
• W2001561654 cites W2118308841 @default.
• W2001561654 cites W2125297546 @default.
• W2001561654 cites W2135741165 @default.
• W2001561654 cites W2140521378 @default.
• W2001561654 cites W2140765540 @default.
• W2001561654 cites W2147944062 @default.
• W2001561654 cites W2162525969 @default.
• W2001561654 cites W2168915540 @default.
• W2001561654 cites W2169047384 @default.
• W2001561654 doi "https://doi.org/10.1161/circulationaha.108.779751" @default.
• W2001561654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18955668" @default.
• W2001561654 hasPublicationYear "2008" @default.
• W2001561654 type Work @default.
• W2001561654 sameAs 2001561654 @default.
• W2001561654 citedByCount "139" @default.
• W2001561654 countsByYear W20015616542012 @default.
• W2001561654 countsByYear W20015616542013 @default.
• W2001561654 countsByYear W20015616542014 @default.
• W2001561654 countsByYear W20015616542015 @default.
• W2001561654 countsByYear W20015616542016 @default.
• W2001561654 countsByYear W20015616542017 @default.
• W2001561654 countsByYear W20015616542018 @default.
• W2001561654 countsByYear W20015616542019 @default.
• W2001561654 countsByYear W20015616542020 @default.
• W2001561654 countsByYear W20015616542021 @default.
• W2001561654 countsByYear W20015616542022 @default.
• W2001561654 countsByYear W20015616542023 @default.
• W2001561654 crossrefType "journal-article" @default.
• W2001561654 hasAuthorship W2001561654A5002047467 @default.
• W2001561654 hasAuthorship W2001561654A5006281057 @default.
• W2001561654 hasAuthorship W2001561654A5018770371 @default.
• W2001561654 hasAuthorship W2001561654A5022121355 @default.
• W2001561654 hasAuthorship W2001561654A5043324136 @default.
• W2001561654 hasAuthorship W2001561654A5043857150 @default.
• W2001561654 hasAuthorship W2001561654A5054116239 @default.
• W2001561654 hasAuthorship W2001561654A5054895539 @default.
• W2001561654 hasAuthorship W2001561654A5057524424 @default.
• W2001561654 hasAuthorship W2001561654A5061019810 @default.
• W2001561654 hasAuthorship W2001561654A5069563229 @default.
• W2001561654 hasAuthorship W2001561654A5083839456 @default.
• W2001561654 hasAuthorship W2001561654A5084935661 @default.
• W2001561654 hasAuthorship W2001561654A5089492075 @default.
• W2001561654 hasBestOaLocation W20015616541 @default.
• W2001561654 hasConcept C121608353 @default.
• W2001561654 hasConcept C126322002 @default.
• W2001561654 hasConcept C134018914 @default.
• W2001561654 hasConcept C164705383 @default.
• W2001561654 hasConcept C170493617 @default.
• W2001561654 hasConcept C184235292 @default.
• W2001561654 hasConcept C185592680 @default.
• W2001561654 hasConcept C2777583451 @default.
• W2001561654 hasConcept C2778019345 @default.
• W2001561654 hasConcept C2778695046 @default.

• next